Phase 3 outcomes from NEJM SURMOUNT-1, SURPASS-2, STEP-1, and Lancet Orforglipron oral GLP-1 trials—plus hepatic dawn phenomenon physiology, 15-minute post-meal GLUT4 walks, and first-30-day Type 2 Diabetes remission protocols. Explore 704 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Treatment responses to ezetimibe/simvastatin and atorvastatin in at-risk patients with the MetS were related to age (≥ 65 years), abdominal obesity, and lower baseline hs-CRP.
For the pharmacometric review of liraglutide, the key questions focused on exposure-response relationships for effects on fasting plasma glucose, hemoglobin A(1c), and calcitonin and on variability in exposure across...
The presence of fat mass and obesity-associated gene risk variants in healthy early postmenopausal women does not adversely affect their response to hormone therapy.
Current available published evidence is insufficient to support an increased risk of AP or cancer associated with GLP-1 agonists.
Dapagliflozin had no effect on markers of bone formation and resorption or BMD after 50 weeks of treatment in both male and post-menopausal female patients whose T2DM was inadequately controlled on metformin.
In diabetic patients with high blood pressure, high-dose telmisartan increased HMW adiponectin levels and improved insulin resistance through activation of PPAR-gamma.
In treatment-naïve patients with T2D, dapagliflozin plus metformin was generally well tolerated and effective in reducing HbA1c, FPG and weight.
Glycaemic control deteriorated in patients with diabetes following high-dose statin therapy.
However, these meta-analyses included a number of studies with a limited follow-up period, thus impairing the possibility to make a proper comparison of the long-term effects of metformin.
Metformin, but not sulfonylurea, appears to reduce subsequent cancer risk.
Considering the average BMI at baseline (32.4 kg/m(2)) these data means a weight reduction of about 3% at 6 months.
The meta-analysis of the available cross-sectional data suggests that T2DM can be considered independently associated with male hypogonadism.
Despite small patient numbers in some sub-populations and the post-hoc nature of the analysis, this does show that the combination of telmisartan plus amlodipine provides an effective, safe and well-tolerated...
Over a 6-month period, transdermal TRT was associated with beneficial effects on insulin resistance, total and LDL-cholesterol, Lpa, and sexual health in hypogonadal men with type 2 diabetes and/or MetS.
A significantly greater proportion of T2DM patients achieved individual and combined lipid targets when.
However, no statistically significant difference was found between the 2 groups in the adiponectin changes from baseline (-1.5% vs -4.9%, p = 0.15).
Mild RI, as determined by the Cockcroft-Gault equation, had no effect on the real-world benefits and safety of liraglutide in this meta-analysis.
The meta-analysis of the available cross-sectional data suggests that MetS can be considered an independent association of male hypogonadism.
To date, results of randomized trials do not suggest any detrimental effect of GLP-1 receptor agonists on heart and blood vessel events.
Patients perceived lower frequency of hypoglycaemia than glimepiride+metformin and lower frequency of hyperglycaemia than metformin.
Treatment responses in type 2 diabetic patients were related to baseline factors, although treatment effects (ezetimibe/simvastatin being more effective than atorvastatin) remained consistent.
Compared with doubling atorvastatin to 80 mg, addition of ezetimibe to atorvastatin 40 mg produced greater improvements in multiple lipid parameters in high-CHD risk patients with T2DM, MetS or neither, consistent with the...
Intrauterine metformin exposure seems to result in elevated SHBG levels in newborns.
In healthy individuals, metformin has opposing actions on fat oxidation during and after exercise.
Incretin-based therapies are effective in blood sugar control and also offer other advantages such as weight loss (exenatide and liraglutide).
Liraglutide treatment combined with OADs led to rapid improvements in FPG and SBP.
In this study, testosterone treatment showed a neutral effect on insulin resistance and blood sugar control and failed to improve high cholesterol, control blood pressure, or reduce visceral fat significantly in Asian Indian...
Placebo), whereas eprosartan did not influence them.
In these studies, CHD risk strata were inversely related to the likelihood of attaining NCEP LDL-C goals, but did not appear to affect the percentage LDL-C change from baseline.
Given the combination of effective blood sugar control and weight benefits, liraglutide is a good option for early add-on therapy for patients on OAD single-drug treatment.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
